BTG PLC Varithena® Receives Finalised Category I CPT Codes (5907V)
November 06 2017 - 1:00AM
UK Regulatory
TIDMBTG
RNS Number : 5907V
BTG PLC
06 November 2017
BTG plc: Varithena(R) receives finalised category I CPT
codes
New payment rates and automatic electronic processing of claims
effective 1 January 2018
London, UK, 6 November 2017: BTG plc (LSE: BTG), the global
specialist healthcare company, notes that the US Centers for
Medicare and Medicaid Services have published the final fee
schedule for new Category I CPT codes for Varithena(R) procedures.
The codes will be effective from 1 January 2018.
The fee schedule details payments for conducting Varithena(R)
treatments in the physician office setting of $1,624.30 for a
single vein and $1,697.02 for multiple veins. The new CPT codes
define Medicare payment rates and enable automatic and electronic
processing of claims, providing physicians in the US with further
predictability of payment and streamlining the reimbursement
process.
"We believe the new CPT codes are appropriate and have the
potential to underpin our current expectations for the product,"
commented Louise Makin, BTG's CEO. "However, we must wait and see
how they impact physician adoption and insurer practices, and we
should have a better understanding of that by the end of 2018."
For further information contact
BTG
Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536
Chris Sampson, Corporate Communications Director
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178
FTI Consulting
Ben Atwell/Simon Conway
+44 (0)20 3727 1000
About BTG
BTG is a global specialist healthcare company bringing to market
innovative products in specialist areas of medicine to better serve
doctors and their patients. We have a portfolio of Interventional
Medicine products to advance the treatment of cancer, severe
emphysema, severe blood clots and varicose veins, and Specialty
Pharmaceuticals that help patients overexposed to certain
medications or toxins. Inspired by patient and physician needs, BTG
is investing to expand its portfolio to address some of today's
most complex healthcare challenges. To learn more about BTG, please
visit: btgplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDMMGMGKRGNZZ
(END) Dow Jones Newswires
November 06, 2017 02:00 ET (07:00 GMT)
Btg (LSE:BTG)
Historical Stock Chart
From Apr 2024 to May 2024
Btg (LSE:BTG)
Historical Stock Chart
From May 2023 to May 2024